A.Giaccari1 · G. Gliozzo1 · G. Ciccarelli1 · G. Di Giuseppe1 · C. Castellano2 · S. Cum3 · L. Delle Monache4,13 · M. Gallo5 ·M.Lastretti6 · G. Medea7 · M. Monesi8 · R. Napoli9 · B. Pintaudi10 · E. Succurro11 · G. Turchetti
Received: 9 January 2026 / Accepted: 17 March 2026 © The Author(s) 2026
Abstract
Background and aims Although continuous glucose monitoring (CGM) devices are now standard of care among Type 1 diabetes patients, they are still relatively underutilized in Type 2 diabetes (T2D), particularly in those patients not treated with insulin. Widespread adoption continues to be hindered by a combination of factors. Chief among these is the scarcity of long-term, large-scale clinical trials demonstrating the benefits of the use of CGM in T2D. This meta-analysis aimed to address this gap by comparing CGM with self-blood glucose monitoring (SBMG), with primary outcomes of HbA1c and time in range (TIR) in insulin-treated and non-insulin-treated TD2 patients.
Methods and results Following the stringent rules mandated by our National Health Service (which requires a panel com-posed of all stakeholders involved in diabetes treatment, and includes PICO, GRADE, AGREE, and meta-analyses), we performed a systematic review of RCTs that enrolled two groups of individuals with T2D, those treated with insulin (includ-ing basal and basal-bolus regimens), and those receiving treatments other than insulin. All included trials compared CGM with structured blood glucose monitoring (SBGM) with glycated hemoglobin (HbA1c) as the main endpoint. Based on the strength and consistency of the evidence, the panel issued a strong recommendation in favor of CGM for individuals with T2D treated with insulin (including those on basal insulin alone) and for individuals with T2D not treated with insulin, par-ticularly for those with glycated hemoglobin levels≥7%. From a pharmacoeconomic perspective, outcomes were positive in both patient groups.
Conclusion CGM represents a clinically effective and cost-efficient approach to optimizing glycemic control in T2D, becom-ing mandatory among individuals on insulin therapy. Our findings support a shift in clinical practice toward the more widespread use of CGM in T2D, with regulatory frameworks and reimbursement policies needing to adapt accordingly.
Keywords CGM · Type 2 Diabetes · Metanalysis · PICO · GRADE · Guidelines
Communicated by Massimo Federici, M.D.
A. Giaccari 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
1 Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy
2 Azienda USL of Modena, Sassuolo Hospital, Sassuolo, Italy
3 Diabetes and Diabetic Foot Care Unit, ASUGI, Monfalcone, Italy
4 National Board Member of FAND (Italian Association for the Rights of Diabetic People), Roma, Italy
5 Department of Endocrinology and Metabolic Diseases, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
6 Order of Psychologists of Lazio, Rome, Italy
7 Italian Society of General Medicine (SIMG), Florence, Italy
8 Territorial Diabetology Unit, AUSL Ferrara, Ferrara, Italy
9 Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
10 Diabetes Unit, Niguarda Cà Granda Hospital, Milan, Italy
11 Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
12 Institute of Management, Scuola Superiore Sant’Anna, Pisa, Italy
13 Patient Advocacy Lab, ALTEMS – Università Cattolica del Sacro Cuore, Rome, Italy
版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章。
引用本文:简喜超, 简扬, 邓呈亮. 2025版《中国糖尿病足防治实践指南》解读[J]. 中华医学美学美容杂志, 2026, 32(2): 99-103. DOI: 10.3760/cma.j.cn114657-20251215-00266.
通信作者:邓呈亮,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
很多糖尿病患者,一提起腹痛,就会想到这多半是消化科和胃肠外科的疾病,其实不然,对于糖尿病病人而言,你还应该重视糖尿病酮症酸中毒。
是的,糖尿病酮症酸中毒会出现腹痛,这是它的不典型症状,先给大家讲几个案例。
案例一
患者,男性,18岁,因“上腹痛、多饮伴体重下降2周,加重伴呕吐、烦躁2天”入院。患者2周前无诱因出现上腹烧灼样疼痛,伴有反酸、乏力,同时有多饮、多尿和体重下降。
外院消化科就诊,胃镜检查示胃小弯处溃疡,诊断为胃溃疡,给予信法丁、果胶泌和吗丁林等药物治疗无好转,症状呈加重的趋势。
2天前出现失眠、烦躁、淡漠,转诊去同一家医院神经内科,给予舒乐安定1毫克、阿米替林25毫克等对症治疗,症状无改善,并于次日清晨出现意识模糊伴恶心、呕吐。即收入住院。
这位患者表现为上腹痛伴多饮、消瘦,根据胃镜检查结果给予相应治疗后症状无改善,病情进行性加重,并出现神志改变,在给予对症治疗后病情无缓解时,急查生化后才发现血糖显著升高和尿酮体阳性,明确了糖尿病酮症酸中毒的诊断。
经积极补液和小剂量胰岛素持续静滴,2天后酮症酸中毒得到纠正,之后改为胰岛素皮下注射,血糖控制理想出院。
案例二
患者,男性,41岁,农民,因“腹痛2天”入院,患者2天前出现上腹部痛,并呕吐。当地医院诊断“急性胃炎”,给予抗炎,解痉,补糖水治疗。腹痛未见好转,出现神志改变,精神差,嗜睡。查血淀粉酶为625U/L,腹部B超:胰腺稍肿大,不排除胰腺炎。急诊科以“急性胰腺炎”收入住院外科。
入院急查血生化:血糖21mmol/L,二氧化碳结合力15mmol/L,血酮7.2mmol/L, 尿常规:尿酮(+++),尿糖(+++),请内分泌科会诊后诊断为糖尿病酮症酸中毒。
案例三
患者,女,63岁,因“腹泻1天,持续右上腹绞痛3小时”入院。患者1天前无明显诱因出现腹泻,3-5次/天,质稀,味臭。自服阿莫西林2片,每天3次,3小时前出现右上腹绞痛。既往史:有十二指肠溃病史3年,否认糖尿病史。
查体:体温 37.6℃,血压132/67毫米汞柱。精神差,皮肤干燥,呼吸急促,躁动不安,腹稍膨隆,全腹压痛及反跳痛明显,听诊肠鸣音减弱。摄腹部X线平片疑膈下有游离气体;查血白细胞13.2×109/L。诊断:弥漫性腹膜炎,不除外十二指肠球部溃疡穿孔,行剖腹探查术。术中未发现穿孔部位,关腹。
请内科会诊术后查血糖26.2mmol/L,尿糖(++++),尿酮体(++),确诊为糖尿病酮症酸中毒,予胰岛素、纠正酸中毒、补液等治疗,病情逐渐好转。
酮症酸中毒为什么会出现腹痛?
酮症酸中毒为什么会出现腹痛?我想这是很多人看完上述病例的感受,被误诊、漏诊是非常可怕的,当然,糖尿病患者腹痛除了糖尿病酮症酸中毒,可能合并其它引起腹痛的疾病。
众所周知,糖尿病酮症酸中毒是一种以高血糖、高酮血症和代谢性酸中毒为主要特点的综合征,属于糖尿病患者急性并发症,会导致糖与脂肪代谢紊乱,患者主要以恶心、头痛、烦躁等为早期症状,后期症状以严重脱水、脉搏细速、血压下降等为主,如果患者对以腹痛为首发表现的症状不给于高度重视,常常会增加漏诊率和误诊率,贻误治疗时机。
糖尿病酮症酸中毒的诊断标准是:血糖>13.9mmol/L;血酮≥3.0mmol/L;尿酮体阳性(++以上);血气分析:pH<7.3。
而目前认为糖尿病酮症酸中毒发生腹痛的原因可能有:
本文旨在提醒所有糖尿病病人发生腹痛时,多一个心眼,血糖、血酮、尿常规、电解质一定要监测,自己也要测下血糖,勿要延误治疗时机。当然,防治糖尿病酮症酸中毒才是最安全的,糖友一定要引起重视。
暴饮暴食不可有,尽量不要漏打胰岛素,平时注意监测血糖,尽量维持血糖在11.1mmol/L以下,降糖方案的调整最好在专业医生的指导下进行,尽量规避感染(感染是酮症酸中毒的最大诱因)、多喝水(除外严重心衰、肾衰病人等)、保持平和稳定的心态。愿所有糖友都不要经历糖尿病酮症酸中毒的痛苦!
作者:沐欣欣
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。